Related Experiment Video
Updated: Apr 8, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
AT-101 inhibits hedgehog pathway activity and cancer growth
Juan Wang1, Yuanqiu Peng, Yuan Liu
1Department of Pharmacology, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, People's Republic of China.
Purpose:
AT-101 is considered as a putative pan-inhibitor of anti-apoptotic Bcl-2 family protein members acting as a BH3 mimetic. It is currently being investigated in phase I/II clinical trial in various types of cancers. In this study, using a series of in vitro and in vivo assays, we evaluated the effect of AT-101 on the hedgehog (Hh) signaling pathway activity and its anticancer ability.
Results:
We found that AT-101 obviously blocked the Hh signaling pathway activity in response to ShhN-conditioned medium (ShhN CM). This inhibitory effect, to some extent, displayed selectivity against Hh signaling pathway. Furthermore, we identified that AT-101 potentially acted on smoothened (Smo) by sharing the same binding site with cyclopamine, a classical Hh signaling pathway inhibitor. Taking advantage of the patch+/-; p53-/- mouse medulloblastoma model, we observed that AT-101 significantly suppressed the Hh-driven medulloblastoma growth in vitro and in vivo.
Conclusions:
This study demonstrates that AT-101 significantly and selectively inhibits Hh pathway activity by potentially targeting Smo and consequently suppresses the growth of Hh-driven cancer. Therefore, this study reveals a novel molecular mechanism responsible for the anticancer action of AT-101 and contributes to the further development of AT-101 as an anticancer drug.
Insights
AT-101, a Bcl-2 inhibitor, effectively blocks the hedgehog (Hh) signaling pathway by targeting Smo. This action suppresses Hh-driven cancers, revealing a novel anticancer mechanism for AT-101 development.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- AT-101 is a BH3 mimetic investigated as a pan-inhibitor of anti-apoptotic Bcl-2 family proteins.
- The hedgehog (Hh) signaling pathway is implicated in various cancers, making it a therapeutic target.
Purpose of the Study:
- To evaluate the effect of AT-101 on Hh signaling pathway activity.
- To assess the anticancer ability of AT-101 in Hh-driven cancers.
Main Methods:
- In vitro and in vivo assays were employed.
- The study utilized a patch+/-; p53-/- mouse medulloblastoma model.
- Binding site analysis with cyclopamine was performed to understand AT-101's mechanism.
Main Results:
- AT-101 demonstrated significant inhibition of Hh signaling pathway activity.
- The inhibition showed selectivity towards the Hh pathway.
- AT-101 was found to potentially target Smo, sharing a binding site with cyclopamine.
- AT-101 suppressed Hh-driven medulloblastoma growth both in vitro and in vivo.
Conclusions:
- AT-101 selectively inhibits the Hh pathway by targeting Smo.
- This inhibition leads to the suppression of Hh-driven cancer growth.
- The study reveals a novel mechanism for AT-101's anticancer action, supporting its development.
Related Concept Videos
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression

